ArticleBiomicrofluidics2017
Flow reproducibility of whole blood and other bodily fluids in simplified no reaction lateral flow assay devices.
Article in Biomicrofluidics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 43 citations in OpenAlex.
- Translational opportunities in aptamer and nanobody lateral flow assays within the WHO REASSURED framework.Sensors & diagnostics · 2026Review
- Magnetically Retrievable Platinum Nanoreporters for Efficient Lateral Flow Immunoassay in Complex Bio-Samples.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Paper-based microfluidics: Analyte-driven imbibition under the lens.Biomicrofluidics · 2025Article
- Comparison of Day-Specific Serum LH, Estradiol, and Progesterone with MiraMedicina (Kaunas, Lithuania) · 2024Article
- Toward Next Generation Lateral Flow Assays: Integration of Nanomaterials.Chemical reviews · 2022Review
- Microfluidics geometries involved in effective blood plasma separation.Microfluidics and nanofluidics · 2022Review
- Evolving Paradigm of Prothrombin Time Diagnostics with Its Growing Clinical Relevance towards Cardio-Compromised and COVID-19 Affected Population.Sensors (Basel, Switzerland) · 2021Review
- A Simple Distance Paper-Based Analytical Device for the Screening of Lead in Food Matrices.Biosensors · 2021Article
- Norovirus detection in water samples at the level of single virus copies per microliter using a smartphone-based fluorescence microscope.Nature protocols · 2021Article
- Sputum Processing Method for Lateral Flow Immunochromatographic Assays to Detect Coronaviruses.Immune network · 2021Article
- Eliminating viscosity bias in lateral flow tests.Microsystems & nanoengineering · 2021Article
- CFD simulations for paper-based DNA amplification reaction (LAMP) of Mycobacterium tuberculosis-point-of-care diagnostic perspective.Medical & biological engineering & computing · 2020Article
- Engineering a simple lateral flow device for animal blood coagulation monitoring.Biomicrofluidics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The "no reaction" lateral flow assay (nrLFA) uses a simplified LFA structure with no conjugate pad and no stored reagents. In the nrLFA, the capillary-based transport time or distance is the key indicator, rather than the outcome of a biochemical reaction. Hence, the calibration and reproducibility of the nrLFA device are critical. The capillary flow properties of several membrane types (nitrocellulose, nylon, cellulose acetate, polyethersulfone, and polyvinylidene difluoride) are evaluated. Flow rate evaluations of MilliporeSigma Hi-Flow™ Plus (HF075, HF135 and HF180) nitrocellulose membranes on nrLFA are performed using bodily fluids (whole blood, blood plasma, and artificial sweat). The results demonstrate that fluids with lower viscosity travel faster, and membranes with slower flow rate exhibit higher capability to distinguish fluids with different viscosities. Reproducibility tests of nrLFA are performed on HF075, demonstrating excellent reproducibility. The coefficient of variation for blood coagulation tests performed with the nrLFA using induced coagulation was 5% for the plasma front and 2% for the RBC front. The effects of variation in blood hematocrit and sample volume are also reported. The overall results indicate that the nrLFA approach has a high potential to be commercially developed as a blood monitoring point-of-care device with simple calibration capability and excellent reproducibility.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.